JENKEM(688356)2025-01-17 09:50Revenue Projections - The company expects to achieve an annual revenue of approximately CNY 223 million in 2024, a decrease of CNY 69.12 million or 23.66% compared to the previous year [4]. - The previous year's revenue was CNY 292.12 million, and the net profit attributable to the parent company was CNY 115.74 million [7]. Net Profit Estimates - The projected net profit attributable to the parent company for 2024 is estimated to be between CNY 23.5 million and CNY 28 million, representing a decrease of CNY 87.74 million to CNY 92.24 million, or a decline of 75.81% to 79.70% year-on-year [5]. - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is estimated to be between CNY 16.5 million and CNY 19 million, a decrease of CNY 93.19 million to CNY 95.69 million, or a decline of 83.06% to 85.29% year-on-year [5]. Market Conditions - The company is undergoing a performance transformation period, with a significant decline in domestic orders due to price competition and pressure from downstream commercialization product prices [9]. - The overseas market is experiencing a customer structure adjustment, with a slight decrease in orders from overseas medical device clients, while orders from pharmaceutical clients have significantly increased due to new drug launches [9]. Financial Reporting - The performance forecast has not been audited by a registered accountant and is based on preliminary calculations by the company's financial department [10]. - The company emphasizes that the forecast data is preliminary and the accurate financial data will be disclosed in the audited 2024 annual report [12].